• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ICID 2008 Summaries: Japanese Encephalitis

mixin

Well-known member
Final abstract number: 55.002

Japanese Encephalitis in Indonesia: New Findings on Geographical Extent and Disability from the Disease

Background: A two-year prospective study was conducted from January 2005to December 2006 to estimate the magnitude of Japanese encephalitis (JE) disease burden in Indonesia. All children 15 years of age and under presenting with acute encephalitis syndrome (AES) to selected hospital and health center sites were identified and laboratory testing was conducted to confirm
the proportion of cases due to JE virus infection. Epidemiological data were collected to improve understanding of JE disease in Indonesia.

Methods: Six provinces with different assumed risks for JE virus transmission were included. At fifteen hospital and health center sites, paired sera, cerebrospinal fluid samples, and at some sites filter paper specimens, were taken from patients who met the WHO criteria for AES. They were tested for antibody to JE and dengue viruses using immunoglobulin M antibody capture
ELISA at the National Institute of Health Research and Development in Jakarta.

Results: 1496 AES patients (1401 from hospitals, 95 from health centers) were recorded. 74.9% (n = 1120) were <5 years old, and 57.6% (n = 862) were male. 82 patients (5.5%) had IgM antibody to JE virus: of these, 70.7 % (n = 58) were aged <5 years, and 56.1% (n = 46) were males. The average length of hospitalization of JE positive patients was significantly longer than those who tested JE negative (12.7 days and 8.8 days, respectively; p = 0.03); they were also more likely to suffer from sequelae than those without JE (RR = 3.12 ; p <0.001). Having pig rearing nearby (less than 5 km from the house) was the main risk factor associated with acute JE infection (p = 0.004). However, about half of the JE patients did not live close to a pig population, suggesting that other amplifying hosts such as water birds are also involved in JE virus transmission in Indonesia.

Conclusion: JE patients were found in all study sites, and sequelae were found in a high proportion of patients. A national program of JE vaccination is certainly worth consideration.

E.R. Sedyaningsih1, S. Ompusunggu1, S. Hills2, N.K. Susilarini1, V. Moniaga2, A. Sasmito2, D. Yuwono1, G. Wahyuhono1, M. Sembiring Maha1, A. Suwandono1
1National Institute of Health Research and Development, Jakarta, Indonesia, 2Program for Appropriate Technology in Health, Seattle, USA, 2Program for Appropriate Technology in Health, Jakarta, Indonesia

http://www.isid.org/13th_icid/index.shtml
 
Re: ICID 2008 Summaries: Japanese Encephalitis

Final abstract number: 55.001
Measuring Japanese Encephalitis Disease Burden: Challenges in Surveillance and Diagnostics

Japanese encephalitis (JE) is a significant but solvable public health problem. Safe, effective, andaffordable vaccines are available to prevent thisdevastating disease. However, the introduction or expansion of JE immunization programs is often delayed because disease burden is unknown
or underestimated. In several countries where JE virus transmission has been proven andsporadic cases have been recognized, JE surveillance does not exist. In other countries, the quality and accuracy of existing surveillance data are uncertain.

Although WHO has published JE surveillance standards, these guidelines have yet to be implemented in most countries. Therefore, the numbers and characteristics of JE cases cannot be easily compared betweencountries or over time. In addition, long-term sequelae associated with JE are often not measured, resulting in an underestimate of the full economic and social impact of the disease.

Most JE cases are diagnosed based on clinical syndrome (i.e., encephalitis) without laboratory confirmation. This practice can perpetuate established biases in the epidemiology of JE because cases are only reported from known endemic areas during predefined transmission seasons. As a result, JE may be underreported from areas that lack well-defined seasonal peaks in encephalitis cases, or among patients with unique clinical presentations (i.e., acute flaccid paralysis) or demographics (i.e., adults). In addition, encephalitis cases due to other etiologies are erroneously attributed to JE virus infection and sometimes misclassified as vaccine failures or vaccine-associated adverse events.

Although many laboratories perform JE diagnostic testing, several steps are needed to ensure the accuracy, reliability, and comparability of the results. Laboratories supporting surveillance efforts should use validated diagnostic assays and standardized testing protocols with strong quality assurance and quality control programs. Improved surveillance with accurate laboratory-based diagnostics is an essential step for better understanding the epidemiology and true burden of JE, and for directing and evaluating effective
immunization strategies.

M. Fischer1, S. Hills2, E. Staples1, B. Johnson1, M. Yaich2, T. Solomon3
1CDC, Fort Collins, CO, USA, 2PATH, Seattle, WA, USA, 3University of Liverpool, Liverpool,
United Kingdom
 
Back
Top